CD8A and neoplasm: For use as adjuvant in DC-based tumor vaccines, the DOX-TCL- and SK-TCL-loaded mature DCs exhibited the highest activity in promoting splenocyte and CD8+ T-cell proliferations, the rapamycin-derived autophagosome loaded mDCs (Rapa-AS-mDCs, Fig 3) exhibited the least effect.